Article
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Cytotherapy - 1 Jul 2023
Karvouni Maria, Vidal-Manrique Marcos, Susek Katharina H, Hussain Alamdar, Gilljam Mari, Zhang Yanliang, Gray J Dixon, Lund Johan, Kaufmann Gunnar, Ljunggren Hans-Gustaf, Ji Henry, Lundqvist Andreas, Wagner Arnika K, Guo Wenzhong, Alici Evren
Abstract excerpt
BACKGROUND AIMS: Adoptive cell therapy with chimeric antigen receptor (CAR)-expressing natural killer (NK) cells is an emerging approach that holds promise in multiple myeloma (MM). However, the generation of CAR-NK cells targeting CD38 is met with obstacles due to the expression of CD38 on NK cells. Knock-out of CD38 is currently explored as a strategy, although the consequences of the lack of CD38 expression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.